Table 1

Synergistic inhibition of in vivo tumor angiogenesis by ENDO, TNP-470, and DI-TSPa

TreatmentMVDa
Control110 ± 17
TNP
 (10 mg/kg/day)45 ± 18
 (30 mg/kg/day)22 ± 9
DI-TSPa
 (20 mg/kg/day)57 ± 17
 (100 mg/kg/day)16 ± 8
ENDO
 (2.5 mg/kg/day)73 ± 7
 (20 mg/kg/day)27 ± 11
TNP/DI-TSPa
 (10 mg/kg/day TNP + 20 mg/kg/day DI-TSPa)76 ± 9
TNP/ENDO
 (10 mg/kg/day TNP + 2.5 mg/kg/day ENDO)28 ± 6
DI-TSPa/ENDO
 (20 mg/kg/day DI-TSPa + 2.5 mg/kg/day ENDO)25 ± 9
  • a Mice bearing Lewis lung carcinoma cells were treated with s.c. injections of antiangiogenic agents as described above for 15 days. The tumors were then excised, fixed, and processed for determination of MVD. Data we reported as the mean MVD of individual 200× Fields counted from each tumor (n = 5 for each dosage tested), where the greatest amounts of neovascularization were observed.